Crossref
Semaglutide’s CVD indication could cost US Medicare $145bn extra a year
BMJ · 2024
DOI: 10.1136/bmj.q1878 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMJ, 2024. Verfasst von Elisabeth Mahase. Beteiligte Einrichtung: The BMJ. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Medicare, Cardiovascular Diseases. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Glucagon-Like PeptidesMedicareCardiovascular DiseasesUnited StatesHumansHypoglycemic AgentsDiabetes Mellitus, Type 2Drug CostsSemaglutide
Substanzen
Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide
Autor:innen und Institutionen
- The BMJ.
Zitieren
APA
Mahase, E. (2024). Semaglutide’s CVD indication could cost US Medicare $145bn extra a year. BMJ. https://doi.org/10.1136/bmj.q1878
Vancouver
Mahase E. Semaglutide’s CVD indication could cost US Medicare $145bn extra a year. BMJ. 2024. doi:10.1136/bmj.q1878
BibTeX
@article{Mahase2024,
author = {Mahase, Elisabeth},
title = {Semaglutide’s CVD indication could cost US Medicare $145bn extra a year},
journal = {BMJ},
year = {2024},
doi = {10.1136/bmj.q1878}
}
EUVIMED